{"&cites=11639266862263687873&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","url":"https://science.sciencemag.org/content/304/5676/1497.abstract","authors":["JG Paez","JG Paez PA Jänne","JG Paez PA Jänne JC Lee","JG Paez PA Jänne JC Lee S Tracy","JG Paez PA Jänne JC Lee S Tracy H Greulich…"],"year":2004,"numCitations":10315,"pdf":"http://mauriciolema.webhost4life.com/rolmm/downloads/files/mEGFR_Science_2004.pdf","citationUrl":"http://scholar.google.com/scholar?cites=15612827971548072563&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:c8pn31Hoq9gJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15612827971548072563&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org","p":1,"exp":1596876800880},{"title":"Epithelial–mesenchymal transitions in tumour progression","url":"https://www.nature.com/articles/nrc822?cacheBust=1509404196362","authors":["JP Thiery"],"year":2002,"numCitations":7037,"pdf":"https://www.researchgate.net/profile/Jean_Thiery/publication/232041706_C_2002_Nature_Publishing_Group/links/0fcfd5073703d5d981000000/C-2002-Nature-Publishing-Group.pdf","citationUrl":"http://scholar.google.com/scholar?cites=2272376285520312713&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ibl1LjEaiR8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=2272376285520312713&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa052122","authors":["EH Romond","EH Romond EA Perez","EH Romond EA Perez J Bryant…"],"year":2005,"numCitations":5935,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa052122","citationUrl":"http://scholar.google.com/scholar?cites=11297359856054390435&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:o07h3-5IyJwJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11297359856054390435&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa033025","authors":["D Cunningham","D Cunningham Y Humblet","D Cunningham Y Humblet S Siena…"],"year":2004,"numCitations":5773,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa033025","citationUrl":"http://scholar.google.com/scholar?cites=15395209161452654085&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:BY45PyrFptUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15395209161452654085&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa052306","authors":["MJ Piccart"],"year":2005,"numCitations":5369,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa052306","citationUrl":"http://scholar.google.com/scholar?cites=1796034903430917809&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:se4zlzrM7BgJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1796034903430917809&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer …","url":"https://www.sciencedirect.com/science/article/pii/S014067361061121X","authors":["YJ Bang","YJ Bang E Van Cutsem","YJ Bang E Van Cutsem A Feyereislova","YJ Bang E Van Cutsem A Feyereislova HC Chung…"],"year":2010,"numCitations":5278,"pdf":"http://www.academia.edu/download/49922633/Bang_YJ_Van_Cutsem_E_Feyereislova_A_Chun20161027-4663-1ti6fgq.pdf","citationUrl":"http://scholar.google.com/scholar?cites=5876984730907239948&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:DOYepHk-j1EJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5876984730907239948&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer","url":"http://www.quantason.com/pdf/HER_2_and_Trastuzumab.pdf","authors":["CL Vogel","CL Vogel MA Cobleigh","CL Vogel MA Cobleigh D Tripathy…"],"year":2002,"numCitations":3567,"pdf":"http://www.quantason.com/pdf/HER_2_and_Trastuzumab.pdf","citationUrl":"http://scholar.google.com/scholar?cites=18217907854524590742&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:lqq8y6sC0_wJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=18217907854524590742&hl=en&as_sdt=2005&sciodt=0,5","publication":"quantason.com"},{"title":"ERBB receptors and cancer: the complexity of targeted inhibitors","url":"https://www.nature.com/articles/nrc1609","authors":["NE Hynes","NE Hynes HA Lane"],"year":2005,"numCitations":3508,"pdf":"https://www.ibyme.org.ar/archivos/capacitacion/t3-r1.pdf","citationUrl":"http://scholar.google.com/scholar?cites=12884418949943547966&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:PliyOMWmzrIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12884418949943547966&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","url":"http://pharmrev.aspetjournals.org/content/56/2/185.short","authors":["G Minotti","G Minotti P Menna","G Minotti P Menna E Salvatorelli","G Minotti P Menna E Salvatorelli G Cairo…"],"year":2004,"numCitations":3452,"pdf":"https://patofyziologie.lf1.cuni.cz/file/538/antracykliny%20(Minotti%202004).pdf","citationUrl":"http://scholar.google.com/scholar?cites=17540166999302556043&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:i0l1PvQwa_MJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17540166999302556043&hl=en&as_sdt=2005&sciodt=0,5","publication":"ASPET"},{"title":"EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma","url":"https://www.journal-of-hepatology.eu/article/S0168-8278(11)00873-7/abstract","authors":["European Association For The Study Of …"],"year":2012,"numCitations":3445,"pdf":"https://www.journal-of-hepatology.eu/article/s0168-8278%2811%2900873-7/fulltext","citationUrl":"http://scholar.google.com/scholar?cites=7958211669914551938&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ggagcFk_cW4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=7958211669914551938&hl=en&as_sdt=2005&sciodt=0,5","publication":"journal-of-hepatology.eu"}]}